Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells.

  title={Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells.},
  author={İhsan Alur and Yavuz Dodurga and M{\"u}cahit Seçme and Levent Elmas and Gulseren Bagci and Ibrahim G{\"o}kşin and Çığır Biray Avcı},
  volume={585 2},

Figures and Tables from this paper

Effect of Some Natural Products on Hepatocellular Carcinoma
Preliminary screening of anticancer activity of Demsisa and fenugreek extracts and oil against HepG2 cells is demonstrated, which can be further used for the development of a potential therapeutic anticancer agent.
Pharmacogenomics and Pharmacoproteomics Studies ofPhosphodiesterase-5 (PDE5) Inhibitors and Paclitaxel Albumin-StabilizedNanoparticles as Sandwiched Anti-Cancer Nano Drugs between TwoDNA/RNA Molecules of Human Cancer Cells
The next important step in the treatment might be done by reducing the anti-cancer Nano drugs such as phosphodiesterase-5 (PDE5) inhibitors and paclitaxel albuminstabilized nanoparticles to the scale of DNA/RNA molecules of human cancer cells.
Antioxidant and anticancer activities of Trigonella foenum-graecum, Cassia acutifolia and Rhazya stricta
R. stricta is introduced as a potentially useful anti-metastatic agent and a novel potential anti-tumour agent for hepatocellular carcinoma (HCC) treatment and is found to be consistent with their antioxidant activity.
The Status of p53 Oligomeric and Aggregation States in Cancer
How misfolding and prion-like amyloid aggregation of p53 seem to play a crucial role in cancer development is addressed and the misfolded and aggregated states of mutant p53 are prospective targets for the development of novel therapeutic strategies against tumoral diseases.
Pharmacogenomics and its Implementations
Later on, pharmacogenomics will permit the advancement of custom-made medications to treat an extensive variety of wellbeing issues, including cardiovascular illness, Alzheimer infection, growth, HIV/AIDS, and asthma.


Oleuropein induces anti-metastatic effects in breast cancer.
It is demonstrated that OL may induce anti-metastatic effects on human breast cancer cells, and the MMPs and TIMPs genes were over-expressed after all periods of incubation in treated cancer cells compared to untreated cells, while MMP2 and MMP9 genes were down-regulated, at least initially.
LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells
Findings support a possible role of these molecules as adjuvant drugs in cancer treatment and inhibit angiogenic response elicited by purified VEGF and FGF-2.
Inhibition of p53 sensitizes MCF-7 cells to ceramide treatment.
Analysis of the effect of exogenous ceramide on the cell cycle progression of MCF-7 breast cancer cells shows that in tumors with inactivating mutations of p53, ceramide-based therapies might provide a novel and effective treatment option.
Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells
Among low molecular weight heparins (LMWHs), 100 IU/100 μL concentration of bemiparin was associated with a more pronounced effect on reducing viability of HUVEC after 72 h of incubation, while nadroparin 100-IU/ 100-μL and enoxaparin 100  IU/100-μl showed the least effects.
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
It is reported that in human colorectal cancer cells, TF expression is under control of 2 major transforming events driving disease progression, in a manner dependent on MEK/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3'-kinase (PI3K).
Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients
The available data show that low-molecular-weight heparins (LMWHs) tend to be more effective and safer than vitamin K antagonists (VKA) in improving survival in patients with cancer, and the beneficial effect of anticoagulant treatment is not universal for all patients withcancer.
Heparin in tumor progression and metastatic dissemination.
The potential anticancer activity of heparins is supported by data from in vitro and experimental studies, and the results of prospective, randomized clinical trials to evaluate the effect of low-molecular-weight heparin on cancer survival have created new interest in this area.
Control of apoptosis by p53
The current understanding of p53 illustrates how apoptosis can be integrated into a larger tumor suppressor network controlled by different signals, environmental factors, and cell type.
Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight
Heparin inhibition of endothelial cell proliferation and organization requires a chain length of >8 saccharide units, with maximal inhibition at Mr of 6 kDa, which differs from that required for anticoagulant activity.